- Home
- VRDN vs MMI Comparison
VRDN vs MMI Comparison
Compare VRDN & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- MMI
- Stock Information
- Founded
- VRDN 2006
- MMI 1971
- Country
- VRDN United States
- MMI United States
- Employees
- VRDN N/A
- MMI N/A
- Industry
- VRDN Medical Specialities
- MMI Real Estate
- Sector
- VRDN Health Care
- MMI Finance
- Exchange
- VRDN Nasdaq
- MMI Nasdaq
- Market Cap
- VRDN 1.3B
- MMI 1.2B
- IPO Year
- VRDN N/A
- MMI 2013
- Fundamental
- Price
- VRDN $14.34
- MMI $31.08
- Analyst Decision
- VRDN Strong Buy
- MMI Sell
- Analyst Count
- VRDN 11
- MMI 1
- Target Price
- VRDN $38.50
- MMI $30.00
- AVG Volume (30 Days)
- VRDN 750.1K
- MMI 186.1K
- Earning Date
- VRDN 08-07-2025
- MMI 08-06-2025
- Dividend Yield
- VRDN N/A
- MMI 1.65%
- EPS Growth
- VRDN N/A
- MMI N/A
- EPS
- VRDN N/A
- MMI N/A
- Revenue
- VRDN $302,000.00
- MMI $711,994,000.00
- Revenue This Year
- VRDN N/A
- MMI $11.69
- Revenue Next Year
- VRDN $17,102.33
- MMI $24.07
- P/E Ratio
- VRDN N/A
- MMI N/A
- Revenue Growth
- VRDN 4.86
- MMI 14.79
- 52 Week Low
- VRDN $9.90
- MMI $27.61
- 52 Week High
- VRDN $27.20
- MMI $42.80
- Technical
- Relative Strength Index (RSI)
- VRDN 50.32
- MMI 55.67
- Support Level
- VRDN $14.11
- MMI $29.40
- Resistance Level
- VRDN $16.05
- MMI $31.58
- Average True Range (ATR)
- VRDN 0.74
- MMI 0.91
- MACD
- VRDN -0.13
- MMI 0.08
- Stochastic Oscillator
- VRDN 20.18
- MMI 77.06
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.